South Korea’s Low Reimbursement Rate for Rare Cancer Drugs: Why Only 57.6% Make the Cut
South Korean cancer patients are urging faster access to experimental therapies, citing systemic delays in drug approval and insurance coverage that exacerbate treatment gaps. Despite 95% health insurance coverage, rare ... Read More